Phaseline

Targets › CCR5

CCR5 (C-C chemokine receptor type 5): drug programs, companies and trials

10 programs from 8 companies in 12 trials: 8 Phase 2, 4 Phase 1; Infectious disease, Oncology, Neurology; next expected readout Nov 2026.

Receptor for a number of inflammatory CC-chemokines including CCL3/MIP-1-alpha, CCL4/MIP-1-beta and RANTES and subsequently transduces a signal by increasing the intracellular calcium ion level. May play a role in the control of granulocytic lineage proliferation or differentiation. (UniProt, P51681)

Open in Phaseline: the race on CCR5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Icahn School of Medicine at Mount SinaiMaraviroc
C-C chemokine receptor type 5 antagonist
CCR5Phase 2Long CovidNov 2026
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajalmaraviroc
C-C chemokine receptor type 5 antagonist
CCR5Phase 2HIV-1-infectionJun 2027
Emmanuel CarreraMaraviroc
C-C chemokine receptor type 5 antagonist
CCR5Phase 2Ischemic StrokeDec 2027
CytoDynleronlimab
C-C chemokine receptor type 5 antagonist
CCR5Phase 2Metastatic Colorectal Cancer (mCRC); HIV - Human Immunodeficiency Virus; Mild Cognitive Impairment (MCI) Due to Alzheimer's DiseaseJan 2028
Icahn School of Medicine at Mount SinaiBMS-813160
C-C chemokine receptor type 2 antagonist; C-C chemokine receptor type 5 antagonist
CCR2, CCR5Phase 2Non-small Cell Lung CancerJul 2028
QuantumLeap Healthcare CollaborativeCenicriviroc
C-C chemokine receptor type 5 antagonist; C-C chemokine receptor type 2 antagonist
CCR5, CCR2Phase 2COVID-19Jul 2028
City of Hope Medical Centerlentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells
lentivirus-transduced hematopoietic progenitor cells expressing anti-HIV shRNA targeting T
CCR5Phase 1AIDS-related Non-Hodgkin LymphomaJul 2027
City of Hope Medical CenterSB-728mR-HSPC
Zinc finger nuclease-mediated CCR5 disruption in hematopoietic stem/progenitor cells
CCR5Phase 1HIVJul 2027
National Cancer Institute (NCI)Maraviroc
C-C chemokine receptor type 5 antagonist
CCR5Phase 1HIVJul 2027
AIDS Malignancy ConsortiumLentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-pos
Gene therapy using lentiviral vector expressing CCR5 shRNA, TRIM5alpha, and TAR decoy in a
CCR5, TRIM5Phase 1HIV InfectionMar 2036

Conditions

HIV (2) Ischemic Stroke (1) Non-small Cell Lung Cancer (1) AIDS-related Non-Hodgkin Lymphoma (1) COVID-19 (1) HIV Infection (1) HIV-1-infection (1) Long Covid (1) Metastatic Colorectal Cancer (mCRC) (1) HIV - Human Immunodeficiency Virus (1) Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (1)

Modalities

small molecule (4), mixed (4), antibody (1), other (1)

Companies

Icahn School of Medicine at Mount Sinai (2) City of Hope Medical Center (2) Emmanuel Carrera (1) QuantumLeap Healthcare Collaborative (1) National Cancer Institute (NCI) (1) AIDS Malignancy Consortium (1) Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal (1) CytoDyn (1)

Related targets

CCR2 (2) TRIM5 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.